NASDAQ: TBPH - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

VA Tech Wabag (NSE: WABAG) wins order from CMWSSB for 45 MLD Chennai TTRO plant

Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway

Representative image of enterprise cloud cybersecurity infrastructure illustrating how Accenture plc and Google Cloud are strengthening cloud security defenses against AI-driven cyber threats and multi-cloud security risks.

How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Theravance Biopharma abandons ampreloxetine, pivots to capital preservation strategy

Read More

5 minute read

Pharma Industry News

Theravance Biopharma (NASDAQ: TBPH) drops rare disease drug after Phase 3 failure triggers strategic review

Theravance Biopharma drops its rare disease drug after a Phase 3 failure. Explore what this means for NASDAQ: TBPH and biotech investors.

byPallavi Madhiraju

March 3, 2026

web analytics